Dyslipidemia and Hyperglycemia in Psoriatic Inpatients

Background: Psoriasis is a chronic cutaneous T-cell mediated disease, which has been associated with many comorbidities, especially with metabolic disorders such as dyslipidemia, diabetes mellitus, obesity, and metabolic syndrome, many of which are themselves risk factors for other diseases. The goa...

Full description

Bibliographic Details
Main Authors: Bojan Popchanovski, Margareta Balabanova-Stefanova
Format: Article
Language:English
Published: International Journal of Medical Students 2019-12-01
Series:International Journal of Medical Students
Subjects:
Online Access:http://ijms.info/IJMS/article/view/438
id doaj-29680fa76dbe4157a7c064cb30a1cd55
record_format Article
spelling doaj-29680fa76dbe4157a7c064cb30a1cd552020-11-25T02:48:50ZengInternational Journal of Medical StudentsInternational Journal of Medical Students2076-63272019-12-0173626510.5195/ijms.2019.438438Dyslipidemia and Hyperglycemia in Psoriatic InpatientsBojan Popchanovski0Margareta Balabanova-Stefanova1Medical Faculty, University Ss. Cyril and Methodius, Skopje, Republic of North MacedoniaUniversity Clinic of Dermatology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, Republic of North MacedoniaBackground: Psoriasis is a chronic cutaneous T-cell mediated disease, which has been associated with many comorbidities, especially with metabolic disorders such as dyslipidemia, diabetes mellitus, obesity, and metabolic syndrome, many of which are themselves risk factors for other diseases. The goal of this study was to evaluate the presence of dyslipidemia and hyperglycemia in patients with psoriasis. Methods: We compared 48 inpatients with plaque psoriasis aged 29-79, hospitalized between March 2018 and February 2019, to 48 age- and gender-matched controls. We evaluated dyslipidemia and hyperglycemia using enzymatic methods as part of a standard blood test, or medication history indicative of ongoing treatment of dyslipidemia and/or hyperglycemia. Hypertension was evaluated by registering blood pressure greater than 140/90 mmHg or ongoing antihypertensive treatment. Smoking habits were also noted. Results: There were statistically significant differences between psoriasis patients and controls for elevated total cholesterol (p=0,028), elevated LDL (p=0,015), hypertriglyceridemia (p=0,006), and hyperglycemia (p=0,021). The two groups had statistically insignificant differences for lowered HDL (p=0,084), hypertension (p=1), and smoking (p=0,836). Conclusion: Hypertriglyceridemia, hyperglycemia, and elevated LDL cholesterol were more prevalent in the group containing psoriatic patients compared to the control group. This indicates that further investigation of metabolic abnormalities should be conducted in psoriatic patients which could greatly benefit from early treatment of the aforementioned underlying conditions.http://ijms.info/IJMS/article/view/438psoriasisinpatientsmetabolic syndromedyslipidemiashyperglicemia
collection DOAJ
language English
format Article
sources DOAJ
author Bojan Popchanovski
Margareta Balabanova-Stefanova
spellingShingle Bojan Popchanovski
Margareta Balabanova-Stefanova
Dyslipidemia and Hyperglycemia in Psoriatic Inpatients
International Journal of Medical Students
psoriasis
inpatients
metabolic syndrome
dyslipidemias
hyperglicemia
author_facet Bojan Popchanovski
Margareta Balabanova-Stefanova
author_sort Bojan Popchanovski
title Dyslipidemia and Hyperglycemia in Psoriatic Inpatients
title_short Dyslipidemia and Hyperglycemia in Psoriatic Inpatients
title_full Dyslipidemia and Hyperglycemia in Psoriatic Inpatients
title_fullStr Dyslipidemia and Hyperglycemia in Psoriatic Inpatients
title_full_unstemmed Dyslipidemia and Hyperglycemia in Psoriatic Inpatients
title_sort dyslipidemia and hyperglycemia in psoriatic inpatients
publisher International Journal of Medical Students
series International Journal of Medical Students
issn 2076-6327
publishDate 2019-12-01
description Background: Psoriasis is a chronic cutaneous T-cell mediated disease, which has been associated with many comorbidities, especially with metabolic disorders such as dyslipidemia, diabetes mellitus, obesity, and metabolic syndrome, many of which are themselves risk factors for other diseases. The goal of this study was to evaluate the presence of dyslipidemia and hyperglycemia in patients with psoriasis. Methods: We compared 48 inpatients with plaque psoriasis aged 29-79, hospitalized between March 2018 and February 2019, to 48 age- and gender-matched controls. We evaluated dyslipidemia and hyperglycemia using enzymatic methods as part of a standard blood test, or medication history indicative of ongoing treatment of dyslipidemia and/or hyperglycemia. Hypertension was evaluated by registering blood pressure greater than 140/90 mmHg or ongoing antihypertensive treatment. Smoking habits were also noted. Results: There were statistically significant differences between psoriasis patients and controls for elevated total cholesterol (p=0,028), elevated LDL (p=0,015), hypertriglyceridemia (p=0,006), and hyperglycemia (p=0,021). The two groups had statistically insignificant differences for lowered HDL (p=0,084), hypertension (p=1), and smoking (p=0,836). Conclusion: Hypertriglyceridemia, hyperglycemia, and elevated LDL cholesterol were more prevalent in the group containing psoriatic patients compared to the control group. This indicates that further investigation of metabolic abnormalities should be conducted in psoriatic patients which could greatly benefit from early treatment of the aforementioned underlying conditions.
topic psoriasis
inpatients
metabolic syndrome
dyslipidemias
hyperglicemia
url http://ijms.info/IJMS/article/view/438
work_keys_str_mv AT bojanpopchanovski dyslipidemiaandhyperglycemiainpsoriaticinpatients
AT margaretabalabanovastefanova dyslipidemiaandhyperglycemiainpsoriaticinpatients
_version_ 1724746356046692352